Acadia Pharmaceuticals | ACAD - Current Assets


Acadia Pharmaceuticals reported $1.27B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
ALKERMES USD 1.58B 57.83M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Bristol-Myers Squibb USD 29.77B 1.19B Sep/2026
Cara Therapeutics USD 23.13M 2.2M Sep/2026
Corcept Therapeutics USD 533.87M 94.2M Sep/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
Eisai JPY 866.82B 16.2B Sep/2026
Eli Lilly USD 65.26B 591M Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
J&J USD 56.35B 3.42B Sep/2026
Moderna USD 7.34B 1.53B Sep/2026
Neurocrine Biosciences USD 2.01B 370.7M Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
Prothena USD 273.86M 18.15M Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vanda Pharmaceuticals USD 347.26M 20.23M Dec/2025
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026